While chemoradiotherapy with platinum compounds is one of the standard treatment regimens for patients with head and neck squamous cell carcinoma (HNSCC), some HNSCCs are resistant and persist/recur after this type of treatment. In this study, we showed vandetanib, an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases, plus cisplatin 
INTRODUCTION
Therefore, inhibiting the EGFR pathway is a potential radiosensitization strategy in patients with HNSCC.
Another potential strategy for overcoming radioresistance in HNSCC is angiogenesis inhibition. In addition to preventing the formation of new blood vessels and interrupting the supply of oxygen and nutrients in tumors (18) , anti-angiogenesis therapy alone or in combination with other treatments transiently normalizes the structure and function of tumor vasculature (19).
Thus, anti-angiogenic agents could be used to induce a remodeling of the tumor vasculature, leading to a temporary improvement in tumor perfusion and reoxygenation that potentially enhance the actions of chemo-and radiotherapy (20) . In addition, anti-angiogenic agents have been reported to enhance the tumor cell response to platinum-based chemotherapeutic drugs (21) .
Vandetanib (AstraZeneca, Macclesfield, Cheshire, UK), an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), EGFR and Rearranged during Transfection (RET) tyrosine kinases, has the potential to restore chemo-and radiosensitivity of HNSCC cells.
In a previous study, we found that vandetanib alone and in combination with paclitaxel had beneficial therapeutic effects in an orthotopic mouse model of human HNSCC (22) .
OSC-19 cells were retrovirally infected with the green fluorescent protein and the luciferase gene (OSC-19-luc) as described previously (23) . SCC61 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum (FBS), L-glutamine, sodium pyruvate, nonessential amino acids, a 2-fold vitamin solution (Life Technologies, Inc., Grand Island, NY), and 0.4 μg/mL hydrocortisone. SqCC/Y1 cells were maintained in DMEM/F12 low glucose supplemented with 10% FBS and L-glutamine. JHU028 cells were maintained in RPMI 1640 supplemented with 10% FBS, L-glutamine, sodium pyruvate, and nonessential amino acids. All other HNSCC cells were maintained in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, nonessential amino acids, and a 2-fold vitamin solution. Adherent monolayer cultures were maintained on plastic plates and incubated at 37°C in 5% carbon dioxide and 95% oxygen. The cultures were Mycoplasma-free and maintained for no longer than 12 weeks after they were recovered from frozen stocks.
Rat monoclonal anti-mouse CD31 (platelet-endothelial cell adhesion molecule 1; PECAM), the primary antibody for immunohistochemical analysis, was purchased from BD Pharmingen (San Diego, CA). The secondary antibodies, peroxidase-conjugated goat anti-rat immunoglobulin G1 and Alexa Fluor 594-conjugated goat anti-rat immunoglobulin G, were purchased from Jackson Research Laboratories (West Grove, PA) and Invitrogen (Carlsbad, CA), respectively.
Cell proliferation assay. The antiproliferative activity of cisplatin against HNSCC cells in vitro
was determined using an MTT assay as previously described (24) . Briefly, 17 HNSCC cell lines were plated in 96-well plates in medium. After a 24-h attachment period, the cells were incubated for 72 h in various concentrations of cisplatin (0.01-90 μM) or with PBS alone as a control. Cells were then incubated in medium containing 2% FBS and 0.25 mg/mL MTT for 3 h.
The cells were then lysed in 100 μL dimethylsulfoxide to release formazan. We used an EL-808 96-well plate reader (BioTek Instruments, Winooski, VT) set at an absorbance of 570 nm to quantify the conversion of MTT to formazan. The concentration of vandetanib giving 50% growth inhibition (GI50) for each cell line was calculated using GraphPad Prism 5.01 (GraphPad Software, San Diego, CA). The experiment was repeated at least twice. The vandetanib GI50 was the average of the values from each MTT assay.
in drug-free medium. After 10-12 d of incubation, the cells were stained with 0.5% crystal violet in absolute ethanol, and colonies with more than 50 cells were counted under a dissection microscope.
OSC-19 and HN5 cells were used in further studies, since they were both cisplatin and radiation-resistant, according to results from MTT assay and clonogenic survival assay with 17 HNSCC cell lines. OSC-19 and HN5 cells in culture were exposed to cisplatin (4 μM and 9 μM, respectively) for 1 h, exposed to vandetanib (2 μM and 2.5 μM, respectively) for 6 h, and then irradiated. After treatments, the cells were assayed for colony-forming ability as described above. Plating efficiency was defined as the percentage of cells seeded that grow into colonies under a specific culture condition of a given cell line. The survival fraction, expressed as a function of irradiation, was calculated as the number of colonies counted/(the number of cells seeded x plating efficiency/100). The surviving fraction after 2 Gy (SF2) was used to determine the radiation sensitivity.
Orthotopic nude mouse model of HNSCC. We used an orthotopic nude mouse model of HNSCC because its host microenvironment is more similar to that of patients with HNSCC than that of subcutaneous xenograft models of HNSCC (25) into the tongues of mice as described previously (26) .
Eight to 10 d after the cells were injected, the mice were randomly assigned to 1 of 8 treatment groups (7 or 8 mice per group): (1) control; (2) cisplatin; (3) vandetanib; (4) vandetanib plus cisplatin; (5) radiation; (6) cisplatin plus radiation; (7) vandetanib plus radiation;
Research. Mice bearing tumors in the tongue were locally irradiated with a single dose of 5 Gy using a small-animal irradiator (γ-rays using a cesium-137 source, 4.762 Gy/min). Sodium pentobarbital was administered by intraperitoneal injection at a dose of 50 mg/kg prior to radiation treatment. The mice were immobilized on a customized jig during irradiation with the tumor centered in the 3-cm diameter circular irradiation field. When cisplatin and radiation were combined, cisplatin was given 1 h before single-dose irradiation (27) . When vandetanib and radiation were combined, vandetanib was given 4 h before single-dose irradiation (28) .
Mice were examined twice a week for tumor size and weight loss. Tongue tumor size was measured with microcalipers. Tumor volume was calculated as (A)(B described previously (30) . Animals were anesthetized with 2% isoflurane (Abbott, Abbott Park, IL), and an aqueous solution of luciferin (Xenogen) at 150 mg/kg in a volume of 0.1 mL was injected intraperitoneally 5 min prior to imaging. We used an IVIS 200 Imaging System (Xenogen) to image the animals and Living Image software (Xenogen) to quantify the photons emitted from luciferase-expressing cells. Photon flux was calculated using a rectangular region of interest encompassing the head and neck region of each mouse while in a dorsal position.
Animals were imaged on an almost weekly basis. Before engineered OSC-19-luc cells were used in vivo, we used the IVIS imaging system to confirm in vitro that the cells homogeneously expressed high levels of luciferase.
We euthanized mice by CO 2 asphyxiation when they lost more than 20% of their preinjection body weight or at 50 d after cell injection. Half of the mouse tumors were fixed in formalin and embedded in paraffin for immunohistochemical and hematoxylin-and-eosin staining; the other half were embedded in optimal cutting temperature compound (Miles, Inc., Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at -80°C. Cervical lymph nodes were resected, embedded in paraffin, sectioned, stained with hematoxylin and eosin. The presence of cervical lymph node metastasis was evaluated histologically using one H&E slide which was from a paraffin block prepared for each animal. Immunofluorescence microscopy was performed using a Leica DMLA microscope (Leica Microsystems, Bannockburn, IL) equipped with a 100-watt HBO mercury bulb and filter sets (Chroma, Inc., Brattleboro, VT) to reveal red and blue fluorescent images independently.
Images were captured using a cooled charge-coupled Hamamatsu C5810 camera (Hamamatsu Table S1 ).
Vandetanib plus cisplatin radiosensitized OSC-19 and HN5 cells. In clonogenic survival
assays, radiation alone resulted in a dose-dependent decrease in HN5 and OSC-19 cell survival.
Cell growth inhibition was observed in both cell lines after 1 h of exposure to cisplatin and 6 h of exposure to vandetanib. OSC-19 cells treated with 2 μM vandetanib and 4 μM cisplatin exhibited more growth inhibition than control cells (Fig. 1A) . While the radiosensitizing effect of treatment with 2.5 μM vandetanib and 9 μM cisplatin on HN5 cells was milder than the radiosensitizing effect on OSC-19, both cell lines demonstrated enhancement compared with control cells (Fig. 1B) . after cell inoculation (P = 0.0106; Fig. 2A ). Mice in the cisplatin alone group, vandetanib alone group, radiation alone group, cisplatin plus radiation group, and vandetanib plus radiation group all had smaller tumor volumes than mice in the control group; however, the difference was not statistically significant. In addition, the vandetanib plus cisplatin and radiation group also showed significant antitumor effect compared with the vandetanib alone group, cisplatin alone group, radiation alone group, and the vandetanib plus radiation group (P = 0.0059, P = 0.0039, P = 0.0051, and P = 0.0366, respectively) . To see the effects of the treatment, we also monitored the bioluminescence intensity of OSC-19-luc cells ( Fig. 2C and 2F ). The mice treated with vandetanib plus cisplatin and radiation had a marked reduction in bioluminescence compared to mice in the control group on day 32 significantly (P = 0.0006).
The antitumor effects of treatment with the combination treatment with vandetanib plus cisplatin, and radiation were also observed in the HN5 orthotopic model (Fig. 2B) . The mice treated with vandetanib, cisplatin, and radiation had a significantly lower mean tumor volume than the mice in the control group at day 35 (P < 0.0001). A significant antitumor effect was also observed in the mice treated with vandetanib alone (P = 0.0076), vandetanib plus cisplatin (P < 0.0001) and the mice treated with vandetanib plus radiation (P = 0.0001). The mice treated with vandetanib, cisplatin, and radiation also had a significantly lower mean tumor volume than the mice in the cisplatin alone group and the cisplatin plus radiation group (P = 0.0002 and P = 0.0451, respectively). The antitumor effects of these treatments were confirmed in a repeat animal experiment with OSC-19 and HN5 cells (data not shown). All treatments appeared to be well-tolerated, with no evidence of treatment-related weight loss (data not shown). (P < 0.0001), respectively (P vs. controls). The median survival period for the vandetanib plus cisplatin and radiation group was significantly greater when compared to that for the cisplatin alone group, vandetanib alone group, vandetanib plus cisplatin group, radiation alone group, and vandetanib plus radiation group (P = 0.0003, P <0.0001, P = 0.0007, P = 0.0003, and P = 0.0140, respectively).
All HN5 control mice in the survival study were euthanized within 38 days following cell inoculation (Fig. 2E) 
cisplatin-treated mice, 61.5% of radiation-treated mice, 53.8% of cisplatin and radiation-treated mice, 46.2% of vandetanib plus radiation-treated mice, and 15.3% of vandetanib plus cisplatin and radiation-treated mice (Table 2) . Thus, combination treatment markedly inhibited the development of cervical lymph node metastases, and the difference in cervical lymph node metastasis incidence between mice treated with vandetanib, cisplatin, and radiation and control mice was significant (P = 0.0048). In addition, the vandetanib, cisplatin, and radiation group showed decreased cervical lymph node metastases when compared to the cisplatin alone group, vandetanib alone group, radiation alone group, and the vandetanib plus cisplatin group (P =0.0154, P =0.0414, P =0.0414, P =0.0414, respectively). The difference between the control group and any another treatment group did not reach statistical significance.
In the mice with HN5 tumors, 40.0% of control mice, 11.1% of cisplatin-treated mice, 27.2% of radiation-treated mice, and 18.1% of cisplatin and radiation-treated mice had cervical lymph node metastases. No cervical lymph node metastases were found in vandetanib-treated mice, vandetanib and cisplatin-treated mice, vandetanib and radiation-treated mice, or vandetanib, cisplatin, and radiation-treated mice (Table 2) and the difference for all treatment groups compared to the control group was significant (P <0.05).
Vandetanib with or without cisplatin increased tumor endothelial cell apoptosis and decreased MVD in vivo in OSC-19 xenografts. Immunostaining tumor sections with CD31
antibody showed that the MVD of tumors from mice treated with vandetanib (31.00 ± 3.32; P < 0.0001), vandetanib plus cisplatin (29.92 ± 2.18; P < 0.0001), cisplatin plus radiation (43.42 ± 3.17; P = 0.0118), vandetanib plus radiation (24.08 ± 1.59; P < 0.0001) or vandetanib plus cisplatin and radiation (12.75 ± 1.92; P < 0.0001) was significantly lower than that of tumors in control mice (55.75 ± 3.18; Fig. 3A and B) . The MVD of tumors in the vandetanib plus cisplatin and radiation was also significantly lower than that in the other treatment groups (P <0.001).
TUNEL assay was performed to examine cell apoptosis in vivo. Compared to the percentage of TUNEL-positive cells in the tumors from mice in the control group (0.92% ± 0.29%), the percentages of TUNEL-positive cells in the tumors from mice in all treatment groups were increased significantly (cisplatin, 3.72% ± 0.85%; vandetanib, 11.49% ± 0.67%; vandetanib plus cisplatin, 12.46% ± 1.22%; radiation, 9.98% ± 1.09%; cisplatin plus radiation, 16.58% ± 2.03%; vandetanib plus radiation, 19.03% ± 2.99%; vandetanib plus cisplatin and radiation, 24.41% ± 2.50%). The difference for all treatment groups compared to the control group was significant (P <0.01) (Fig. 3A and 3C ). In addition, the percentages of TUNEL-positive cells in the vandetanib plus cisplatin and radation group were also significantly greater than in the vandetanib alone group, cisplatin alone group, radiation alone group, and the vandetanib plus radiation group (P <0.05). Double immunofluorescence staining for CD31/TUNEL revealed that vandetanib, vandetanib plus cisplatin, and vandetanib plus radiation significantly increased apoptosis for tumor-associated endothelial cells compared to the control group (control, 0%; vandetanib, 5.38 ± 2.51, P =0.0460; vandetanib plus cisplatin, 5.62 ± 2.40, P =0.0306; vandetanib plus radiation, 5.94 ± 2.53, P =0.0304). The apoptosis for tumor-associated endothelial cells was further enhanced when vandetanib was combined with radiation and cisplatin (8.01 ± 2.74; P = 0.0090) (Fig. 3A and 3D) . Chemoradiotherapy with cisplatin remains a standard treatment for patients with HNSCC, with the aim of improving organ preservation as well as patient survival (31) . However, resistance to cisplatin or radiation leading to treatment failure and locoregional recurrence is a critical problem. In addition, cisplatin causes significant treatment-limiting toxicities including such as myelosuppression, nephrotoxicity, ototoxicity and nephrotoxicity, which can be exacerbated by radiotherapy (8, 32) . Therefore, the addition of more selective agents that target cancer cells may enable the reduction of cisplatin and possibly radiation to less toxic doses.
A number of studies have shown that the EGFR and its downstream PI3K pathway mediate radio-resistance (14, 15, 33) . In a phase III randomized trial, Bonner et al. found that patients with locally advanced HNSCC who were treated with radiation plus cetuximab, a monoclonal antibody against EGFR, had better locoregional control, longer disease-free survival, and longer overall survival than patients treated with radiation alone (34) . In addition, antiangiogenic agents have been reported to enhance radioresponsiveness (35) . These previous studies indicate a potentially important role for EGFR and VEGFR signaling in radio-resistance and suggest that blocking these receptors may result in improved response to radiotherapy. Therefore, we evaluated whether the combination of cisplatin and radiotherapy with vandetanib, a potent inhibitor of both VEGFR and EGFR signaling, may represent a valuable therapeutic approach against experimental HNSCC cancer in this study.
In the present study, OSC-19 and HN5 were selected as representative cell lines as relatively cisplatin-and radiation-resistant cell lines from a panel of 17 different HNSCC cell lines. In this study we found a lack of correlation between radiosensitivity and cisplatin sensitivity consistent with the results of previous reports (36, 37) . The effect of cisplatin on radiosensitization on HN5 was weaker than on OSC-19, which is consistent with the GI50 values for cisplatin alone. In the current study, although 1 mg/kg of cisplatin had only a slight antitumor effect, treatment with cisplatin and radiation slowed OSC-19-luc and HN5 tumor growth more than additively. These results are consistent with those of previous studies that led to the widespread use of cisplatin as a radiosensitizer (38) .
In the current study, vandetanib slowed tumor growth to a greater extent than cisplatin alone. Mice treated with vandetanib had significantly longer survival than control mice. These results are consistent with the results of our previous study (22) . However, in our previous study, we found that the GI50 of vandetanib for HN5 cells (2.357) was higher than its GI50 for OSC-19 cells (1.981) (22) , whereas in the current study, we found no significant differences in the antitumor effects of vandetanib in vivo between HN5 tumors and OSC-19-luc tumors. This inconsistency may have arisen because vandetanib's antitumor effects in HNSCC may be a result of the agent's inhibition of VEGF signaling within the tumor microvasculature rather than its direct antiproliferative effects via EGFR signaling inhibition. These inconsistent findings might also reflect the biological differences between the two cell lines. When vandetanib was combined 
with radiation, it did not significantly enhance the response of OSC-19-luc or HN5 tumors to radiation. However, a number of studies have shown that vandetanib enhances radiation effects in preclinical models (28, 39, 40) including HNSCC (41) . This inconsistency may have been due to the relatively low dose of vandetanib (20 mg/kg) used in the current study, differences in vandetanib and/or radiation treatment schedules, and differences in the type of preclinical mouse models used. However, the combined treatment with vandetanib, cisplatin and radiation showed the most marked reduction in OSC-19-luc and HN5 tumor growth and prolongation of survival in orthotopic oral tongue tumor models compared with not only control but also when compared to all of the other treatments. Similar results with significant tumor inhibition by the combination of vandetanib, cytotoxic chemotherapy and radiation have been reported for other xenograft tumor models (42, 43) .
Although vandetanib given with low concentrations of cisplatin has been reported to have synergistic activity in bladder cancer (21) , the addition of cisplatin to vandetanib treatment in our in vivo studies showed only a slight additive effect. Ansiaux et al. reported that the blockade of of VEGFR signaling reduces oxygen consumption rate in tumor cells and cause an early increase in tumor oxygenation (44) . Thus, the mechanism by which treatment with vandetanib plus cisplatin and radiation exerted its antitumor effect could be the result of a short-term increase in blood flow and oxygenation in the tumor, leading to improved delivery of cisplatin, which led to more cisplatin-induced radiosensitization in the current study.
The presence of cervical lymph node metastasis is a critical event for patients with HNSCC (3). In the current study, treatment with vandetanib alone inhibited metastases in HN5 mice; however, cisplatin and/or radiation did not significantly decrease the incidence of cervical lymph node metastases. While the difference was not significant, OSC-19 mice treated with 
vandetanib alone and OSC-19 mice treated with vandetanib plus radiation had a much lower incidence of cervical lymph node metastases than control mice. These findings are consistent with our previous reports in which the blockade of both EGFR and VEGFR-2 pathways decreased the incidence of the neck lymph node metastases of HNSCC (22, 30) . Moreover, treatment with vandetanib, cisplatin, and radiation produced the most marked decrease in cervical lymph node metastasis incidence.
In the present study, immunohistochemical analysis and TUNEL assay revealed that vandetanib significantly decreased tumor MVD and induced apoptosis in tumor and endothelial cells. These findings are consistent with the results of our previous study as well as other studies (22, 28, 39, 40) . Slight decreases in MVD along with enhanced radiation-induced endothelial apoptosis is consistent with a previous report indicating that radiation can kill tumor cells as well as tumor-associated endothelial cells (45) . Again, the combined treatment with vandetanib, cisplatin and radiation showed the most marked induction of apoptosis in tumor and endothelial cells, and suppression of MVD compared with the other treatment groups, indicating that vandetanib enhanced the combined effect of cisplatin and radiation. Finally, we confirmed previous studies' findings that the inclusion of vandetanib leads to inhibition of EGFR activation and its downstream radioresistance-mediating signaling pathways in oral tongue tumors (14, 15) . 
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